The TRANSEVER registry prospectively assessed 12-month clinical outcomes following percutaneous coronary intervention (PCI) with the ISAR SUMMIT polymer-free everolimus-eluting stent. The study was multicentre and conducted across 33 centres in India, enrolling patients undergoing PCI with this device in routine clinical practice. The registry aimed to evaluate both safety and effectiveness in a large, real-world population.
A total of 1,000 patients were enrolled in TRANSEVER, and 996 completed 12-month follow-up as reported. The cohort had a high-risk clinical profile: an acute coronary syndrome (ACS) presentation was recorded in 89.8% of patients, and diabetes mellitus was present in 44.4%. No further granular demographic or lesion-level details were reported in the source.
Procedural outcomes were described as excellent for device performance. The report states that device success was achieved and that final TIMI 3 flow was obtained in all treated lesions. Beyond those measures, the source did not provide additional procedural metrics such as fluoroscopy time, contrast volume, or adjunctive therapies in this summary.
The predefined primary endpoint was target-lesion failure (TLF) at 12 months, a composite of cardiac death, target-vessel myocardial infarction, or clinically driven target lesion revascularisation. Secondary endpoints included the patient-oriented composite endpoint (POCE) — comprising all-cause death, any myocardial infarction, stroke, and revascularization — and definite or probable stent thrombosis.
At 12 months, the registry reported low event rates for both primary and secondary endpoints. Target-lesion failure (TLF) occurred in 15 patients, corresponding to 1.5% of the cohort. The patient‑oriented composite endpoint (POCE) was observed in 21 patients (2.1%). These outcomes were reported for the overall enrolled population; subgroup outcomes or time-to-event analyses were not detailed in the summarized source.
Definite or probable stent thrombosis was reported in 8 patients, equating to 0.8% at 12 months. The article summary characterizes these rates, alongside the low TLF and POCE figures, as indicative of favourable safety for routine clinical use of this polymer-free drug-eluting stent. The authors reported no competing interests. The source did not provide a breakdown of causes of death, bleeding complications, or other adverse events beyond the composite endpoints listed.
The study is registered with the Clinical Trials Registry of India under the identifier CTRI/2022/07/044472. The authors state that all relevant ethical guidelines were followed and list multiple institutional ethics committee approvals at participating centres. The report is a preprint posted on medRxiv (July 18, 2026) and has not been peer reviewed; the source explicitly notes that the findings should not yet be used to guide clinical practice.
The source text for this summary is the preprint abstract and associated declarations; it provides limited methodological and granular outcome detail. Specific limitations such as lack of randomized comparator, details of medical therapy (including antiplatelet regimens), lesion complexity, quantitative angiographic or imaging endpoints, and longer-term follow-up beyond 12 months were not reported in the provided content. As a preprint, results require peer review for external validation and fuller methodological transparency.
In this large, contemporary, real-world registry with a very high proportion of patients presenting with ACS, the polymer-free everolimus-eluting ISAR SUMMIT stent demonstrated favourable 12-month clinical outcomes in the reported cohort: low rates of target-lesion failure (1.5%), POCE (2.1%), and definite/probable stent thrombosis (0.8%). The authors interpret these findings as supporting the safety and effectiveness of the device for routine clinical use, while noting that the report is a preprint and has not undergone peer review.